STOCKS TELEGRAPH

Tag: ERYP stock

  • Erytech Pharma (ERYP) Succumbs to Corrections Premarket After Upsurge on Manufacturing Facility Sale

    Yesterday, the biotech company, Erytech Pharma (ERYP) announced the sale of its manufacturing facility in the U.S. Following the news, the stock surged up by a nice 37.70% as investors responded positively to the huge transaction. Closing the day at $1.68 a share, ERYP has fallen under corrections in today’s premarket on April 26, 2022.

    Source: Hill Dickenson

    At the last check, the stock had subtracted 8.33% and was trading at a price of $1.54 apiece, in the premarket.

    ERYP’s Facility Sale

    According to the press release, the company has agreed to sell its U.S. manufacturing facility to Catalent for a consideration of $44.5 million. Moreover, the roughly 40 employees of ERYP at the facility would be offered Catalent’s employment. The company’s state-of-the-art commercial-scale cell therapy manufacturing facility is situated in Princeton, New Jersey.

    In addition, the companies also plan to enter into a long-term supply agreement. Under the agreement, Catalent will manufacture the company’s lead product candidate for clinical and commercial supply in the U.S. Furthermore, the company will also leverage Catalent’s expertise in late-stage and commercial manufacturing of products in regard to characterization, and commercial production, regulatory inspections, and approvals.

    The company continues to retain its manufacturing facility in Lyon, France, and now plans to focus on developing transformative therapeutics for serious diseases.

    Why the Bullishness on the Sale?

    Investors were immensely bullish on ERYP due to the sale due to multiple reasons. Given the company’s market cap of $40.07 million at the time of writing, the $44.5 million in sales is a huge transaction for the company.

    The company is still in its clinical stage, which means it needs cash for monetizing its product candidates. As per its 2021 year-end financials, the company only had a cash runway into the third quarter of 2022 with a year-end cash balance of $38.1 million. With the capital from this deal, the company now expects its cash balance to total $60 million. Therefore, the company had bought itself two years of runway to develop drugs with a cash runway extending into mid-2024 now.

    Added to this, the company has also improved its success prospects with the long-term supply agreement.

    Conclusion

    Having bought itself two more years of runway, the company now plans to continue assessing further strategic options including partnerships and asset acquisition. Thus, with the right partnerships and capital resources to fund its R&D, the company is on track to succeed in the long term if it continues the current course.

  • Erytech Pharma (ERYP) stock Up Premarket on Publication of Positive Trial Results

    Erytech Pharma (ERYP) stock is trending in the premarket today, April 7, 2022, with shares up over 45%. At the time of writing, the stock had a value of $2.29 per share against its previous close at $1.57. Investors are responding positively to the company’s publication of positive results from the Eryaspase Phase 2 Trial.

    Source: Society of Clinical Research Associate

    ERYP’s Eryapase Phase 2 Trial

    The company’s lead product candidate was being studied in the Phase 2 NOR-GRASPAAL-2016 trial in ALL (Acute Lymphoblastic leukemia) patients by NOPHO (Nordic Society of Pediatric Hematology and Oncology). Blood and bone marrow cancer ALL is the most common type of cancer in children in the U.S. and Europe. Moreover, the trial evaluated the safety and pharmacological profile of eryaspase in ALL patients with hypersensitivity to PEG-asparaginase therapy.

    Results & Publication

    Early Morning today, ERYP announced positive results of the trial being published in the British Journal of Hematology. The paper is titled “Asparaginase Encapsulated in Erythrocytes as Second-line Treatment in Hypersensitive Patients with Acute Lymphoblastic Leukaemia”.

    The company’s lead product candidate demonstrated sustained asparaginsae enzyme activity and safety. Both of which were the primary objectives of the study. ERYP’s CMO Iman El-Hariry shared the company’s excitement over the possibility of an alternative treatment for ALL patients with hypersensitivity to PEG-asparaginase.

    The Bigger Picture

    Despite the ongoing turmoil initially caused by Covid-19 and now fueled by the Russia-Ukraine conflict, the global pharmaceutical industry has remained bullish. Recording a CAGR of 5.6%, it is projected to grow to $1.6 trillion in 2025.

    The pullout of most industries from Russia has taken a toll on all markets. But the pharmaceutical industry has been noticeably slower in doing so. With the matter of life and death at hand, pharmaceutical companies are restructuring and orienting with a focus on the most important treatments and stopping the least important ones in the country. Even the giants like Pfizer have continued their operations there while donating profits to humanitarian causes. While the debate is still at large, most companies are choosing to continue saving lives rather than being entangled in the invasion.

    ERYP’s Position

    The clinical-stage pharmaceutical company has been making some good progress this year. Some of its major milestones for 2022 include BLA submission of eryaspase in ALL in Q2 2022, TNBC Phase 2 trial data in Q3 2022, and pancreatic cancer phase 1 trial results in the second half of this year. Moreover, with over $38 million in the cash balance, the company has enough to fund all its operations into Q3 2022.

  • ERYTECH Pharma S.A. (ERYP) gained in the pre-market; here is why?

    ERYTECH Pharma S.A. (ERYP) surged in the pre-market after announcing a new patent for treating rare metabolic diseases and information on voting rights. ERYP values at $2.01, gaining more than 6.35% compared to yesterday’s closing price. The stock closed at $1.86 at the end of the last trading session. The stock volume was approximately 45.75K shares at the end of the previous trading session.

    ERYTECH Pharma S.A. (ERYP) increased its patent portfolio

    ERYTECH Pharma S.A. (ERYP) announced in a press release that Arginase-1 deficiency (A1D), an uncommon metabolic illness, was granted a U.S. patent. It also covers Oncology, septic shock, and angiogenesis.

    These therapies will help lower abnormal levels of different metabolites, which can occur in some inborn errors of metabolism illnesses. However, hypersensitivity and rapid clearance sometimes overshadow therapeutic benefits. So there’s a big desire for a more bearable ERT.

    Monthly information on voting rights

    ERYP announced the monthly report along with an increased patent portfolio. As of January 31, 2022, the total shares composing the share capital are 31,018,553. The total of brut voting rights is 32,518,339. The total of net voting rights is 32,515,839. The numbers are unchanged compared to the end of December 31, 2021.

    The CEO of ERYP remarks on the new patent

    ERYTECH’s CEO, Gil Beyen, said the company is happy to broaden its patent coverage for its red blood cell technology in rare diseases. In addition to oncology and cancer metabolism, their rare disease patents bolster their technology’s clinical application potential. With positive preclinical evidence in Arginase Deficiency (A1D), the company’s patent estate protects current and future developments and collaborations in this domain.

    Conclusion

    About 310 issued and 45 pending patents encompass 16 patent families owned by ERYTECH, a global patent portfolio. The company looks forward to using the recent development technology to cure other related diseases. The company is keen on increasing the revenue with the new patents joining the company’s revenue stream.